Courageous. Focused. Passionate.

Harnessing the Power of Nature With Precision Science™

Cancer continues to inflict devastating consequences worldwide. Bexion is committed to conquering cancer and to deliver on our commitment, we have assembled a world class leadership team to advance our innovative, targeted cancer therapy platform. Targeted therapy brings significant potential to the fight against cancer and we are relentless in our pursuit to realize this potential.

banner-info
Home2020-01-20T09:17:26-05:00

– Our Platform

An innovative, targeted approach to treating cancer

Our treatment specifically targets unique features of cancer cells, including externalized phosphatidylserine and tumor cell lysosomes by utilizing a small lysosomal protein known as Saposin C.

Learn More

– Our Pipeline

A Pipeline-in-a-Product asset with potential for multiple indications

BXQ-350 is the foundation of our pipeline. Early clinical results have shown a strong safety and tolerability profile.

Learn More

– clinical trials

Update

Our clinical trials are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.

Learn More

Resources

Bexion Resources

Resources

Learn More
View All Resources

News

    Press Release

    Bexion Pharmaceuticals Announces the Addition of Dr. Raymond J. Tesi to Board of Directors

    November 16, 2020

    FOR IMMEDIATE RELEASE Covington, KY November 16, 2020               Bexion Pharmaceuticals, Inc. announced today that it has added RJ. Tesi, M.D. to its Board of Directors. Dr. Tesi has a distinguished career as a biotech entrepreneur and an experienced surgeon. Currently, he is President, Chief Executive Officer and acting Chief Medical Officer of INmune Bio (NASDAQ: ... Read More

      Press Release

      Bexion Pharmaceuticals, Inc. Receives Rare Pediatric Disease Designation

      September 30, 2020

      FOR IMMEDIATE RELEASE [Covington, KY] September 30, 2020 Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announced that the Federal Drug Administration (FDA) has granted the company’s request for rare pediatric disease designation for BXQ-350, Bexion’s lead therapeutic, for the treatment of diffuse intrinsic pontine glioma (DIPG) and ... Read More

      View All Media